{"product_id":"nvo-ansoff-analysis","title":"(NVO) Novo Nordisk A\/S ANSOFF Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Preview—Access the Full Ansoff Matrix Analysis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Novo Nordisk A\/S Ansoff Matrix Analysis gives a concise framework to assess growth via market penetration, market development, product development, and diversification; it’s used for strategy, investment, or planning and shows a real preview\/sample on this page. Purchase the full version to receive the complete, ready-to-use company-specific analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Penetration\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDeepen Diabetes and Obesity Care Share in Existing Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNovo Nordisk A\/S already sells Diabetes, Obesity Care, and cardiovascular therapies across Europe, the Middle East, Africa, Asia, and North America, so the easiest Ansoff move is to win more share from the same base. In 2024, revenue reached DKK 290.4 billion, showing how much scale this core franchise already has. That makes market penetration the best fit for its existing products and geographies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGrow Rare Disease Use in Current Specialty Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNovo Nordisk A\/S already sells rare blood disorder, endocrine, and hormone replacement therapies, so market penetration here means driving deeper use inside the specialist centers that already treat these patients. This fits a high-touch model: fewer accounts, higher engagement, and repeat use can lift share without opening new markets. In rare disease, each center matters more than broad reach.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIncrease Adoption of Insulin Pens and Injection Needles\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNovo Nordisk reported DKK 290.4bn in sales in 2024, and insulin plus GLP-1 care still relies on pens and needles to get medicines into patients’ hands. Its insulin pens, growth hormone pens, and injection needles are used in the same care settings, so stronger device attachment can lift repeat use and defend share in mature markets. With 2024 operating profit of DKK 128.3bn, even small gains in device adoption can support more durable revenue per patient.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eExpand Smart Insulin Support with Dose Check\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNovo Nordisk A\/S can deepen market penetration by pairing advanced insulin pens with Dose Check, which supports dosing in familiar diabetes channels and lifts adherence without changing the core market. With 589 million adults living with diabetes globally in 2024, small gains in convenience and persistence can matter at scale.\u003c\/p\u003e\n\u003cp\u003eThis fits the 2025 base: more use per patient, stronger stickiness, and better device-led share in existing insulin users. Novo Nordisk generated DKK 290.4 billion in revenue in 2024, showing the scale this type of repeat-use support can protect.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDose Check boosts dosing confidence\u003c\/li\u003e\n\u003cli\u003ePens improve daily convenience\u003c\/li\u003e\n\u003cli\u003eSupports retention in current markets\u003c\/li\u003e\n\u003cli\u003eRaises share without new-market risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eReinforce Obesity-Care Presence Through UNICEF Collaboration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNovo Nordisk A\/S can deepen obesity-care market share by using its UNICEF partnership to raise trust and reach in a field where it already sells treatments. UNICEF and WHO report childhood obesity is a growing global issue, with 391 million children and adolescents aged 5-19 living with overweight in 2022, including 160 million with obesity. That gives the alliance clear visibility, credibility, and a direct path to more patients and referrers.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUses an existing strategic tie\u003c\/li\u003e\n\u003cli\u003eBuilds trust in obesity care\u003c\/li\u003e\n\u003cli\u003eSupports awareness and referrals\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNovo Nordisk Can Grow by Deepening Diabetes and Obesity Share\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNovo Nordisk A\/S can win more share in its core diabetes and obesity markets by improving repeat use, device stickiness, and adherence in the same care channels. Revenue was DKK 290.4bn in 2024 and operating profit DKK 128.3bn, so even small share gains can matter. With 589 million adults living with diabetes in 2024, the existing base is still huge.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 revenue\u003c\/td\u003e\n\u003ctd\u003eDKK 290.4bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 op profit\u003c\/td\u003e\n\u003ctd\u003eDKK 128.3bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal diabetes\u003c\/td\u003e\n\u003ctd\u003e589m adults\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eAnalyzes Novo Nordisk A\/S’s growth strategy through market penetration, market development, product development, and diversification.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eHelps teams quickly pinpoint Novo Nordisk A\/S growth options with a clear, easy-to-use Ansoff matrix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eCites authoritative Novo Nordisk sources to validate each Ansoff growth path, enabling quick verification and defensible strategy decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoll Existing Therapies into Additional EMEA and Asia Country Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNovo Nordisk already sells in Europe, the Middle East, Africa, and parts of Asia, so market development means adding more country launches for current therapies, not new products. This fits its global setup: in 2025, the company reported DKK 290.4bn in sales, giving it scale to fund registrations, local access, and distribution across new EMEA and Asia markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBroaden North American Access Channels for Current Products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNorth America is already Novo Nordisk A\/S’s biggest growth engine: in 2024, sales reached DKK 290.4 billion, with U.S.-led demand driving the mix. Broader access via more payers, clinics, and patient pathways can lift reach for current medicines and devices without changing the portfolio. That makes this a low-R\u0026amp;D market-development move with clear scale upside.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExpand in Mainland China, Hong Kong and Taiwan Settings\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNovo Nordisk can grow in Mainland China, Hong Kong and Taiwan by taking the same diabetes, obesity and rare-disease products into more clinics, hospitals and specialty care sites. This fits market development: in 2024, Novo Nordisk reported DKK 290.4bn in revenue and DKK 25.9bn in operating profit, giving it room to widen access. China also has one of the world’s largest diabetes patient pools, so deeper local reach can lift volume without changing the core product mix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eTake Rare Disease Treatments into New Specialty Centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNovo Nordisk A\/S can use the same rare-disease therapies in new specialty centers to reach more hemophilia and endocrine patients without changing the core product. In FY2025, this market-development move should lift access, referral volume, and treatment starts as more centers adopt specialist care.\u003c\/p\u003e\n\u003cp\u003eIt works because rare-disease demand is concentrated: a few trained centers can serve many patients, so each new country or clinic entry expands the addressable base fast. The upside is higher patient reach and deeper local penetration with the same portfolio.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMore specialty centers, more referrals\u003c\/li\u003e\n\u003cli\u003eSame therapies, wider patient access\u003c\/li\u003e\n\u003cli\u003eBest fit for rare blood disorders\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eUse UNICEF Links to Reach New Childhood-Obesity Program Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNovo Nordisk A\/S can use its UNICEF partnership to reach new childhood-obesity program markets without changing its core products; the shift is in access, not the offering. UNICEF works in 190+ countries and territories, so the channel can open doors to public-health and school-based programs that Novo Nordisk A\/S may not reach directly.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSame product base, new access route\u003c\/li\u003e\n\u003cli\u003eTargets childhood-obesity program buyers\u003c\/li\u003e\n\u003cli\u003eUses UNICEF’s global reach: 190+ markets\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNovo Nordisk Expands the Same Portfolio Into New Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNovo Nordisk A\/S’s market development is about pushing the same portfolio into more countries and care sites. In FY2025, sales were DKK 290.4bn, so it has scale to fund registrations, tenders, and local access in EMEA, Asia, and rare-disease centers without changing the product mix.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eFY2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSales\u003c\/td\u003e\n\u003ctd\u003eDKK 290.4bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUse case\u003c\/td\u003e\n\u003ctd\u003eNew countries, same products\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBest fit\u003c\/td\u003e\n\u003ctd\u003eDiabetes, obesity, rare disease\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eNovo Nordisk A\/S Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Ansoff Matrix analysis document you’ll receive upon purchase—no surprises, just professional quality, focused on Novo Nordisk’s growth options across market penetration, product development, market development, and diversification.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdd New Cardiometabolic Therapies in Diabetes and Obesity Care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNovo Nordisk A\/S’s Diabetes and Obesity Care division spans diabetes, obesity, cardiovascular disease, and other emerging areas, so new therapies here are classic product development for existing markets. In FY2024, Novo Nordisk A\/S reported DKK 290.4bn in sales, and obesity care sales rose 57% at CER, showing how core cardiometabolic demand is scaling. New medicines that deepen this base can extend growth without changing the customer set.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDevelop New Treatments for Rare Blood Disorders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNovo Nordisk A\/S can use product development here because its Rare Disease unit already serves the same specialist hematology doctors and centers. In 2024, Novo Nordisk A\/S reported sales of DKK 290.4 billion, showing it has the scale to fund new therapies. New treatments for rare blood disorders extend an existing portfolio, so this is classic product development, not market expansion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExtend Endocrine and Hormone Replacement Offerings\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNovo Nordisk can extend its endocrine and hormone replacement line by adding new formulations and therapies for the same rare-disease market, so the customer base stays unchanged while the product set widens. In 2025, Novo Nordisk reported DKK 290.4 billion in net sales and DKK 31.5 billion in R\u0026amp;D spend, which supports continued work in niche endocrine care. This fits a product development move: deeper use of existing medical channels, but more treatment options for patients with uncommon hormone disorders.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eUpgrade Advanced Insulin Pens\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNovo Nordisk A\/S can upgrade advanced insulin pens with dose-memory, finer dose steps, and easier grip without leaving the diabetes market, so this is a product-extension move. With 589 million adults living with diabetes worldwide in 2025, even small usability gains can matter for adherence and switching.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSame market, better pen\u003c\/li\u003e\n\u003cli\u003eAdd precision and memory\u003c\/li\u003e\n\u003cli\u003eSupport adherence and convenience\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eEnhance Dose Check Digital Guidance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDose Check already sits inside Novo Nordisk A\/S's digital diabetes toolkit, so improving its guidance is a product upgrade in an existing market. Diabetes affected 589 million adults worldwide in 2024, so clearer insulin-dose support can raise confidence, reduce user error, and make the tool more relevant.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eExisting product, existing market\u003c\/li\u003e\n\u003cli\u003eBetter dose guidance\u003c\/li\u003e\n\u003cli\u003eStronger user trust\u003c\/li\u003e\n\u003cli\u003eHigher product relevance\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNovo Nordisk Bets Big on Diabetes and Obesity Innovation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eProduct development in Novo Nordisk A\/S means adding new medicines and device features for the same diabetes and obesity markets. In FY2025, Novo Nordisk A\/S reported DKK 290.4bn in net sales and DKK 31.5bn in R\u0026amp;D spend, giving it room to keep funding pipeline upgrades. Diabetes affected 589 million adults worldwide in 2025, so better therapies can scale fast.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eFY2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet sales\u003c\/td\u003e\n\u003ctd\u003eDKK 290.4bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003eDKK 31.5bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal diabetes cases\u003c\/td\u003e\n\u003ctd\u003e589 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDiversification\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBuild a Digital Diabetes Management Business\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBuilding a digital diabetes management business fits diversification because Novo Nordisk A\/S can extend from medicines into connected care and software-led services. In FY2025, the company generated DKK 290.4 billion in sales, so even a small digital layer can scale across an installed base of millions of diabetes patients treated with its therapies. This adds a new product format and a broader market model, not just another drug.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExpand Medical Equipment into a Medtech Growth Line\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNovo Nordisk already sells insulin pens, growth hormone pens, and injection needles, so expanding this line moves it deeper into medtech, not just drugs. In 2024, the Company reported DKK 290.4 billion in net sales, up 26% year on year, and delivery devices help support that scale by locking in patient use. This is diversification: more revenue from medical devices, broader mix, and less reliance on pure pharma.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDevelop AI-Enabled Cardiometabolic Discovery with Valo Health\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNovo Nordisk’s collaboration with Valo Health gives it an AI-driven route into cardiometabolic discovery, so it is not just defending its core market; it is opening a new innovation path. Cardiometabolic disease affects over 1 billion people worldwide, which keeps the addressable need very large. The move fits Ansoff diversification because it adds a new data-led engine for future drug pipelines and new product bets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eEnter Public-Health Obesity Programs with UNICEF\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNovo Nordisk A\/S’s UNICEF partnership moves beyond drug sales into public-health delivery, targeting childhood obesity through prevention, education, and policy support. That is diversification into a new channel and a wider solution model, not just a new product line.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eWHO: 390 million children overweight in 2022\u003c\/li\u003e\n\u003cli\u003e160 million were living with obesity\u003c\/li\u003e\n\u003cli\u003eNew channel: public-health, not only pharma\u003c\/li\u003e\n\u003cli\u003eBetter reach in prevention-led markets\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis fits a broader market strategy because obesity is a long-run global burden, and UNICEF gives Novo Nordisk access to governments and health systems, where scale can matter more than prescriptions alone.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePackage Integrated Therapy-and-Data Care Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNovo Nordisk A\/S can push diversification by packaging insulin, GLP-1 care, pens, CGM links, and app support into one paid care bundle. That widens the business from pure drug sales into service-linked healthcare delivery, lifting the market interface beyond pharmacies and clinics; Novo Nordisk A\/S reported DKK 232.3bn revenue in 2023, showing scale to support this shift.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBundles raise switching costs\u003c\/li\u003e\n\u003cli\u003eMixes product, device, and data\u003c\/li\u003e\n\u003cli\u003eExpands care beyond the prescription\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNovo Nordisk Expands Beyond Drugs With Digital Care and Devices\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNovo Nordisk A\/S diversification shows up in digital care, devices, and data-led partnerships, moving beyond pure drug sales. In FY2025, net sales were DKK 290.4 billion, so even small non-drug lines can scale fast. This mix widens revenue sources and lowers reliance on one product class.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSignal\u003c\/th\u003e\n\u003cth\u003eFY2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet sales\u003c\/td\u003e\n\u003ctd\u003eDKK 290.4bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCore shift\u003c\/td\u003e\n\u003ctd\u003eDrugs to care bundle\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRisk\u003c\/td\u003e\n\u003ctd\u003eLower concentration\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234734612745,"sku":"nvo-ansoff-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/nvo-ansoff-matrix.webp?v=1785726942","url":"https:\/\/dcfanalyst.com\/products\/nvo-ansoff-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}